Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.

Linda Gelb accelerates groundbreaking team science by supporting the Bridge Project

Linda and Art Gelb
Linda and Art Gelb

Fall 2026
By Michael Quinn

Art Gelb, a longtime Dana-Farber Cancer Institute Trustee and supporter, was deeply admired for his vision, intelligence, persistence, and philanthropic leadership. While Art passed in 2023, his inspiring legacy endures in the Bridge Project, a powerful research collaboration between Dana-Farber/Harvard Cancer Center and the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.

Recently, Art’s widow Linda made a generous gift of $1 million to establish the Arthur Gelb and Ronald Gelb Endowed Fund in support of the Bridge Project, co-directed by James DeCaprio, MD and MIT leadership. Named for Art and their late son Ron, the fund will provide perpetual resources to propel new studies and create the biennial Arthur Gelb Symposium. The symposium will bring researchers across Dana-Farber and MIT together to highlight their breakthroughs and catalyze new innovations in cancer medicine.

As a respected board member of both institutions, Art saw the immense potential of a program that combines the clinical expertise of Dana-Farber faculty with the scientific and engineering prowess of MIT investigators. Fueled by his encouragement and philanthropy, the Bridge Project launched in 2011 to advance knowledge, technologies, and treatments that improve patients’ lives and address the most formidable challenges in cancer. Since then, 127 collaborative projects have received critical seed funding through Bridge Project awards, leading to 163 influential publications, 52 invention disclosures and patents, and at least 28 initiatives with direct patient impact.

For example, Dana-Farber and MIT researchers leveraged Bridge Project funding to enhance NeoVax, a personalized cancer vaccine pioneered at Dana-Farber that targets the unique mutations in a patient’s tumor. The team harnessed machine learning tools to optimize vaccine design and developed novel delivery methods to maximize the anti-tumor immune response across multiple cancers. This innovative approach has shown promise in treating melanoma, glioblastoma, renal and ovarian cancers, follicular lymphoma, and chronic lymphocytic leukemia, among others.

Such synergistic progress is precisely what Art had in mind when he convinced Dana-Farber and MIT researchers to cross the bridge between their respective campuses and forge productive partnerships. According to Linda, the Bridge Project was what Art was most proud of among his many achievements, and she aims to secure its future through her endowment. “Cancer has affected our entire family, and Art was committed to mobilizing brilliant teams against this disease through the Bridge Project,” she said. “I am honored to help support them so they can continue to accelerate advancements, generate hope, and elevate patient outcomes.”

More stories:

Copy link
Powered by Social Snap